Fig. 2From: Safety and tolerability of nintedanib in patients with progressive fibrosing interstitial lung diseases: data from the randomized controlled INBUILD trialRate of decline in FVC (mL/year) over 52 weeks by nintedanib dose adjustment in the INBUILD trialBack to article page